Unusual Causes of Cutaneous Ulceration

Surgical Clinics of North America

Volumn 90, Issue 6, 2010, Pages 1161-1180

  Panuncialman, Jaymie ^a   Falanga, Vincent ^a,b  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calciphylaxis; Cryofibrinogenemia; Inflammatory ulcers; Pyoderma gangrenosum; Vasculitis

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; DAPSONE; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PENTOXIFYLLINE; THALIDOMIDE; WARFARIN;

CALCINOSIS; CHOLESTEROL EMBOLISM; CRYOGLOBULINEMIA; DIAGNOSTIC ERROR; HUMAN; INFLAMMATION; NECROBIOSIS LIPOIDICA; NEUROPATHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; REVIEW; SKIN BIOPSY; SKIN NECROSIS; SKIN ULCER; VASCULAR DISEASE; VASCULITIS; WOUND CARE; WOUND DRESSING;

BIOPSY, NEEDLE; CALCIPHYLAXIS; CHRONIC DISEASE; COMBINED MODALITY THERAPY; EMBOLISM, CHOLESTEROL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; NECROSIS; PAIN MEASUREMENT; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SKIN CARE; SKIN ULCER; VASCULITIS; WOUND HEALING;

EID: 78149419869     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2010.08.006     Document Type: Review

References (119)

1. Herber O.R., Schnepp W., Rieger M.A. A systematic review on the impact of leg ulceration on patients' quality of life. Health Qual Life Outcomes 2007, 5:44.
2. Panuncialman J., Falanga V. The science of wound bed preparation. Clin Plast Surg 2007, 34(4):621-632.
3. Brunsting L.A., Goeckerman W.H., O'Leary P.A. Pyoderma (ecthyma) gangrenosum: clinical and experimental observations in 5 cases occurring in adults. Arch Derm Syphilol 1930, 22:655-680.
4. Weenig R.H., Davis M.D., Dahl P.R., et al. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med 2002, 347(18):1412-1418.
5. Powell F.C., Schroeter A.L., Su W.P., et al. Pyoderma gangrenosum: a review of 86 patients. Q J Med 1985, 55(217):173-186.
6. Powell F.C., Su W.P., Perry H.O. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996, 34(3):395-409. [quiz: 410-2].
7. Duguid C.M., O'Loughlin S., Otridge B., et al. Paraneoplastic pyoderma gangrenosum. Australas J Dermatol 1993, 34(1):17-22.
8. Langan S.M., Powell F.C. Vegetative pyoderma gangrenosum: a report of two new cases and a review of the literature. Int J Dermatol 2005, 44(8):623-629.
9. Hughes A.P., Jackson J.M., Callen J.P. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000, 284(12):1546-1548.
10. Sheldon D.G., Sawchuk L.L., Kozarek R.A., et al. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg 2000, 135(5):564-568. [discussion: 568-9].
11. Hubbard V.G., Friedmann A.C., Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol 2005, 152(5):1059-1061.
12. Field S., Powell F.C., Young V., et al. Pyoderma gangrenosum manifesting as a cavitating lung lesion. Clin Exp Dermatol 2008, 33(4):418-421.
13. Kanoh S., Kobayashi H., Sato K., et al. Tracheobronchial pulmonary disease associated with pyoderma gangrenosum. Mayo Clin Proc 2009, 84(6):555-557.
14. Kruger S., Piroth W., Amo Takyi B., et al. Multiple aseptic pulmonary nodules with central necrosis in association with pyoderma gangrenosum. Chest 2001, 119(3):977-978.
15. Ross H.J., Moy L.A., Kaplan R., et al. Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment. Cancer 1991, 68(2):441-443.
16. Montoto S., Bosch F., Estrach T., et al. Pyoderma gangrenosum triggered by alpha2b-interferon in a patient with chronic granulocytic leukemia. Leuk Lymphoma 1998, 30(1-2):199-202.
17. Sanders S., Busam K., Tahan S.R., et al. Granulomatous and suppurative dermatitis at interferon alfa injection sites: report of 2 cases. J Am Acad Dermatol 2002, 46(4):611-616.
18. Srebrnik A., Shachar E., Brenner S. Suspected induction of a pyoderma gangrenosum-like eruption due to sulpiride treatment. Cutis 2001, 67(3):253-256.
19. Brooklyn T.N., Williams A.M., Dunnill M.G., et al. T-cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking. Br J Dermatol 2007, 157(5):960-966.
20. Magro C.M., Kiani B., Li J., et al. Clonality in the setting of Sweet's syndrome and pyoderma gangrenosum is not limited to underlying myeloproliferative disease. J Cutan Pathol 2007, 34(7):526-534.
21. Su W.P., Davis M.D., Weenig R.H., et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 2004, 43(11):790-800.
22. Su W.P., Schroeter A.L., Perry H.O., et al. Histopathologic and immunopathologic study of pyoderma gangrenosum. J Cutan Pathol 1986, 13(5):323-330.
23. Matis W.L., Ellis C.N., Griffiths C.E., et al. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 1992, 128(8):1060-1064.
24. Bennett M.L., Jackson J.M., Jorizzo J.L., et al. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000, 79(1):37-46.
25. Chow R.K., Ho V.C. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996, 34(6):1047-1060.
26. Vidal D., Puig L., Gilaberte M., et al. Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features. J Dermatolog Treat 2004, 15(3):146-152.
27. Elgart G., Stover P., Larson K., et al. Treatment of pyoderma gangrenosum with cyclosporine: results in seven patients. J Am Acad Dermatol 1991, 24(1):83-86.
28. Prystowsky J.H., Kahn S.N., Lazarus G.S. Present status of pyoderma gangrenosum. Review of 21 cases. Arch Dermatol 1989, 125(1):57-64.
29. Johnson R.B., Lazarus G.S. Pulse therapy. Therapeutic efficacy in the treatment of pyoderma gangrenosum. Arch Dermatol 1982, 118(2):76-84.
30. Reichrath J., Bens G., Bonowitz A., et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005, 53(2):273-283.
31. Wolverton S. Comprehensive dermatologic drug therapy 2007, Elsevier, Philadelphia. 2nd edition.
32. Adisen E., Oztas M., Gurer M.A. Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy?. Dermatology 2008, 216(2):163-165.
33. Brooklyn T.N., Dunnill M.G., Shetty A., et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006, 55(4):505-509.
34. Regueiro M., Valentine J., Plevy S., et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003, 98(8):1821-1826.
35. Romero-Gomez M., Sanchez-Munoz D. Infliximab induces remission of pyoderma gangrenosum. Eur J Gastroenterol Hepatol 2002, 14(8):907.
36. Mimouni D., Anhalt G.J., Kouba D.J., et al. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 2003, 148(4):813-816.
37. Roy D.B., Conte E.T., Cohen D.J. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol 2006, 54(3 Suppl 2):S128-S134.
38. Goldenberg G., Jorizzo J.L. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatolog Treat 2005, 16(5-6):347-349.
39. Pastor N., Betlloch I., Pascual J.C., et al. Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept). Clin Exp Dermatol 2006, 31(1):152-153.
40. Charles C.A., Leon A., Banta M.R., et al. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol 2007, 46(10):1095-1099.
41. Nousari H.C., Lynch W., Anhalt G.J., et al. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol 1998, 134(12):1509-1511.
42. Daniels N.H., Callen J.P. Mycophenolate mofetil is an effective treatment for peristomal pyoderma gangrenosum. Arch Dermatol 2004, 140(12):1427-1429.
43. Hecker M.S., Lebwohl M.G. Recalcitrant pyoderma gangrenosum: treatment with thalidomide. J Am Acad Dermatol 1998, 38(3):490-491.
44. Hagman J.H., Carrozzo A.M., Campione E., et al. The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum. J Dermatolog Treat 2001, 12(1):19-22.
45. Altman J., Mopper C. Pyoderma gangrenosum treated with sulfone drugs. Minn Med 1966, 49(1):22-26.
46. Lally A., Hollowood K., Bunker C.B., et al. Penile pyoderma gangrenosum treated with topical tacrolimus. Arch Dermatol 2005, 141(9):1175-1176.
47. Kontos A.P., Kerr H.A., Fivenson D.P., et al. An open-label study of topical tacrolimus ointment 0.1% under occlusion for the treatment of pyoderma gangrenosum. Int J Dermatol 2006, 45(11):1383-1385.
48. de Imus G., Golomb C., Wilkel C., et al. Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression. J Am Acad Dermatol 2001, 44(1):61-66.
49. Carlson J.A., Cavaliere L.F., Grant-Kels J.M. Cutaneous vasculitis: diagnosis and management. Clin Dermatol 2006, 24(5):414-429.
50. Carlson J.A., Ng B.T., Chen K.R. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol 2005, 27(6):504-528.
51. Chen K.R., Carlson J.A. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 2008, 9(2):71-92.
52. Ioannidou D.J., Krasagakis K., Daphnis E.K., et al. Cutaneous small vessel vasculitis: an entity with frequent renal involvement. Arch Dermatol 2002, 138(3):412-414.
53. Grzeszkiewicz T.M., Fiorentino D.F. Update on cutaneous vasculitis. Semin Cutan Med Surg 2006, 25(4):221-225.
54. Sais G., Vidaller A., Jucgla A., et al. Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol 1998, 134(3):309-315.
55. Carlson J.A., Chen K.R. Cutaneous vasculitis update: small vessel neutrophilic vasculitis syndromes. Am J Dermatopathol 2006, 28(6):486-506.
56. Carlson J.A., Chen K.R. Cutaneous vasculitis update: neutrophilic muscular vessel and eosinophilic, granulomatous, and lymphocytic vasculitis syndromes. Am J Dermatopathol 2007, 29(1):32-43.
57. Chen K.R. Cutaneous polyarteritis nodosa: a clinical and histopathological study of 20 cases. J Dermatol 1989, 16(6):429-442.
58. Lapraik C., Watts R., Scott D.G. Modern management of primary systemic vasculitis. Clin Med 2007, 7(1):43-47.
59. Bosch X., Guilabert A., Espinosa G., et al. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA 2007, 298(6):655-669.
60. Keon W.J., Heggtveit H.A., Leduc J. Perioperative myocardial infarction caused by atheroembolism. J Thorac Cardiovasc Surg 1982, 84(6):849-855.
61. Falanga V., Fine M.J., Kapoor W.N. The cutaneous manifestations of cholesterol crystal embolization. Arch Dermatol 1986, 122(10):1194-1198.
62. Fine M.J., Kapoor W., Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology 1987, 38(10):769-784.
63. Moolenaar W., Lamers C.B. Cholesterol crystal embolisation to the alimentary tract. Gut 1996, 38(2):196-200.
64. Rushovich A.M. Perforation of the jejunum: a complication of atheromatous embolization. Am J Gastroenterol 1983, 78(2):77-82.
65. Belenfant X., Meyrier A., Jacquot C. Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis 1999, 33(5):840-850.
66. Gore I., McCombs H.L., Lindquist R.L. Observations on the fate of cholesterol emboli. J Atheroscler Res 1964, 4:527-535.
67. Bruns F.J., Segel D.P., Adler S. Control of cholesterol embolization by discontinuation of anticoagulant therapy. Am J Med Sci 1978, 275(1):105-108.
68. Kawakami Y., Hirose K., Watanabe Y., et al. Management of multiple cholesterol embolization syndrome-a case report. Angiology 1990, 41(3):248-252.
69. Donohue K.G., Saap L., Falanga V. Cholesterol crystal embolization: an atherosclerotic disease with frequent and varied cutaneous manifestations. J Eur Acad Dermatol Venereol 2003, 17(5):504-511.
70. Scolari F., Ravani P., Pola A., et al. Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study. J Am Soc Nephrol 2003, 14(6):1584-1590.
71. Dauden E., Onate M.J. Calciphylaxis. Dermatol Clin 2008, 26(4):557-568. ix.
72. Oh D.H., Eulau D., Tokugawa D.A., et al. Five cases of calciphylaxis and a review of the literature. J Am Acad Dermatol 1999, 40(6 Pt 1):979-987.
73. Weenig R.H., Sewell L.D., Davis M.D., et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007, 56(4):569-579.
74. Kalajian A.H., Malhotra P.S., Callen J.P., et al. Calciphylaxis with normal renal and parathyroid function: not as rare as previously believed. Arch Dermatol 2009, 145(4):451-458.
75. Essary L.R., Wick M.R. Cutaneous calciphylaxis. An underrecognized clinicopathologic entity. Am J Clin Pathol 2000, 113(2):280-287.
76. Monney P., Nguyen Q.V., Perroud H., et al. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant 2004, 19(8):2130-2132.
77. Shiraishi N., Kitamura K., Miyoshi T., et al. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 2006, 48(1):151-154.
78. Hanafusa T., Yamaguchi Y., Tani M., et al. Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates. J Am Acad Dermatol 2007, 57(6):1021-1025.
79. Byrnes C.A., Shepler B.M. Cinacalcet: a new treatment for secondary hyperparathyroidism in patients receiving hemodialysis. Pharmacotherapy 2005, 25(5):709-716.
80. Sharma A., Burkitt-Wright E., Rustom R. Cinacalcet as an adjunct in the successful treatment of calciphylaxis. Br J Dermatol 2006, 155(6):1295-1297.
81. Velasco N., MacGregor M.S., Innes A., et al. Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy?. Nephrol Dial Transplant 2006, 21(7):1999-2004.
82. Brucculeri M., Cheigh J., Bauer G., et al. Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. Semin Dial 2005, 18(5):431-434.
83. Hayden M.R., Tyagi S.C., Kolb L., et al. Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol 2005, 4(1):4.
84. Guerra G., Shah R.C., Ross E.A. Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous haemofiltration using low calcium replacement fluid: case report. Nephrol Dial Transplant 2005, 20(6):1260-1262.
85. Hafner J., Keusch G., Wahl C., et al. Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol 1995, 33(6):954-962.
86. Arch-Ferrer J.E., Beenken S.W., Rue L.W., et al. Therapy for calciphylaxis: an outcome analysis. Surgery 2003, 134(6):941-944. [discussion: 944-5].
87. Dereure O., Leray H., Barneon G., et al. Extensive necrotizing livedo reticularis in a patient with chronic renal failure, hyperparathyroidism and coagulation disorder: regression after subtotal parathyroidectomy. Dermatology 1996, 192(2):167-170.
88. Amdo T.D., Welker J.A. An approach to the diagnosis and treatment of cryofibrinogenemia. Am J Med 2004, 116(5):332-337.
89. Nash J.W., Ross P., Neil Crowson A., et al. The histopathologic spectrum of cryofibrinogenemia in four anatomic sites. Skin, lung, muscle, and kidney. Am J Clin Pathol 2003, 119(1):114-122.
90. Smith S.B., Arkin C. Cryofibrinogenemia: incidence, clinical correlations, and a review of the literature. Am J Clin Pathol 1972, 58(5):524-530.
91. Blain H., Cacoub P., Musset L., et al. Cryofibrinogenaemia: a study of 49 patients. Clin Exp Immunol 2000, 120(2):253-260.
92. Falanga V., Kirsner R.S., Eaglstein W.H., et al. Stanozolol in treatment of leg ulcers due to cryofibrinogenaemia. Lancet 1991, 338(8763):347-348.
93. Revenga F., Aguilar C., Gonzalez R., et al. Cryofibrinogenaemia with a good response to stanozolol. Clin Exp Dermatol 2000, 25(8):621-623.
94. Copeman P.W. Cryofibrinogenaemia and skin ulcers: treatment with plasmapheresis. Br J Dermatol 1979, 101(Suppl 17):57-58.
95. Kirsner R.S., Eaglstein W.H., Katz M.H., et al. Stanozolol causes rapid pain relief and healing of cutaneous ulcers caused by cryofibrinogenemia. J Am Acad Dermatol 1993, 28(1):71-74.
96. Rubegni P., Flori M.L., Fimiani M., et al. A case of cryofibrinogenaemia responsive to stanozolol. Br J Haematol 1996, 93(1):217-219.
97. Williamson A.E., Cone L.A., Huard G.S. Spontaneous necrosis of the skin associated with cryofibrinogenemia, cryoglobulinemia, and homocystinuria. Ann Vasc Surg 1996, 10(4):365-369.
98. Chartier M., Falanga V. Healing of ulcers due to cryofibrinogenemia with colchicine and high-dose pentoxifylline. Am J Clin Dermatol 2009, 10(1):39-42.
99. Braverman I.M. Skin signs of systemic disease 1997, W.B. Saunders, Philadelphia. 3rd edition.
100. Peyri J., Moreno A., Marcoval J. Necrobiosis lipoidica. Semin Cutan Med Surg 2007, 26(2):87-89.
101. Zeichner J.A., Stern D.W., Lebwohl M. Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2006, 54(3 Suppl 2):S120-S121.
102. Noz K.C., Korstanje M.J., Vermeer B.J. Ulcerating necrobiosis lipoidica effectively treated with pentoxifylline. Clin Exp Dermatol 1993, 18(1):78-79.
103. Harth W., Linse R. Topical tacrolimus in granuloma annulare and necrobiosis lipoidica. Br J Dermatol 2004, 150(4):792-794.
104. Reinhard G., Lohmann F., Uerlich M., et al. Successful treatment of ulcerated necrobiosis lipoidica with mycophenolate mofetil. Acta Derm Venereol 2000, 80(4):312-313.
105. Stinco G., Parlangeli M.E., De Francesco V., et al. Ulcerated necrobiosis lipoidica treated with cyclosporin A. Acta Derm Venereol 2003, 83(2):151-153.
106. Stanway A., Rademaker M., Newman P. Healing of severe ulcerative necrobiosis lipoidica with cyclosporin. Australas J Dermatol 2004, 45(2):119-122.
107. De Rie M.A., Sommer A., Hoekzema R., et al. Treatment of necrobiosis lipoidica with topical psoralen plus ultraviolet A. Br J Dermatol 2002, 147(4):743-747.
108. Durupt F., Dalle S., Debarbieux S., et al. Successful treatment of necrobiosis lipoidica with antimalarial agents. Arch Dermatol 2008, 144(1):118-119.
109. Miura Y., Ardenghy M., Ramasastry S., et al. Coumadin necrosis of the skin: report of four patients. Ann Plast Surg 1996, 37(3):332-337.
110. Chan Y.C., Valenti D., Mansfield A.O., et al. Warfarin induced skin necrosis. Br J Surg 2000, 87(3):266-272.
111. Ward C.T., Chavalitanonda N. Atypical warfarin-induced skin necrosis. Pharmacotherapy 2006, 26(8):1175-1179.
112. Wynn S.S., Jin D.K., Essex D.W. Warfarin-induced skin necrosis occurring four days after discontinuation of warfarin. Haemostasis 1997, 27(5):246-250.
113. Franson T.R., Rose H.D., Spivey M.R., et al. Late-onset, warfarin-caused necrosis occurring in a patient with infectious mononucleosis. Arch Dermatol 1984, 120(7):927-931.
114. DeFranzo A.J., Marasco P., Argenta L.C. Warfarin-induced necrosis of the skin. Ann Plast Surg 1995, 34(2):203-208.
115. Tai C.Y., Ierardi R., Alexander J.B. A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency. Ann Vasc Surg 2004, 18(2):237-242.
116. Rose V.L., Kwaan H.C., Williamson K., et al. Protein C antigen deficiency and warfarin necrosis. Am J Clin Pathol 1986, 86(5):653-655.
117. Nazarian R.M., Van Cott E.M., Zembowicz A., et al. Warfarin-induced skin necrosis. J Am Acad Dermatol 2009, 61(2):325-332.
118. Hunter J.B., Lonsdale R.J., Wenham P.W., et al. Heparin induced thrombosis: an important complication of heparin prophylaxis for thromboembolic disease in surgery. BMJ 1993, 307(6895):53-55.
119. Warkentin T.E., Elavathil L.J., Hayward C.P., et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997, 127(9):804-812.